IOVA
Price:
$8.555
Market Cap:
$2.61B
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center;...[Read more]
Industry
Biotechnology
IPO Date
2010-10-15
Stock Exchange
NASDAQ
Ticker
IOVA
According to Iovance Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.78. This represents a change of -15.19% compared to the average of -6.82 of the last 4 quarters.
The mean historical PE Ratio of Iovance Biotherapeutics, Inc. over the last ten years is -10.78. The current -5.78 PE Ratio has changed 5.26% with respect to the historical average. Over the past ten years (40 quarters), IOVA's PE Ratio was at its highest in in the September 2023 quarter at -2.46. The PE Ratio was at its lowest in in the December 2020 quarter at -24.84.
Average
-10.78
Median
-8.10
Minimum
-24.95
Maximum
-2.61
Discovering the peaks and valleys of Iovance Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 304.58%
Maximum Annual PE Ratio = -2.61
Minimum Annual Increase = -70.78%
Minimum Annual PE Ratio = -24.95
Year | PE Ratio | Change |
---|---|---|
2023 | -4.31 | 64.95% |
2022 | -2.61 | -70.78% |
2021 | -8.93 | -64.19% |
2020 | -24.95 | 35.60% |
2019 | -18.40 | 164.09% |
2018 | -6.97 | 22.88% |
2017 | -5.67 | -21.93% |
2016 | -7.26 | -41.41% |
2015 | -12.39 | -24.14% |
2014 | -16.34 | 304.58% |
The current PE Ratio of Iovance Biotherapeutics, Inc. (IOVA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.28
5-year avg
-11.84
10-year avg
-10.78
Iovance Biotherapeutics, Inc.’s PE Ratio is greater than PTC Therapeutics, Inc. (-8.15), less than Krystal Biotech, Inc. (99.38), less than Sarepta Therapeutics, Inc. (99.56), greater than Madrigal Pharmaceuticals, Inc. (-13.02), less than CureVac N.V. (0), less than Apellis Pharmaceuticals, Inc. (5.71), greater than Mirati Therapeutics, Inc. (-16.72), greater than CohBar, Inc. (-11.26), less than Rain Therapeutics Inc. (-0.12), less than Ocean Biomedical, Inc. (-1.51), less than Hepion Pharmaceuticals, Inc. (-0.41), less than null (-0.18),
Company | PE Ratio | Market cap |
---|---|---|
-8.15 | $3.70B | |
99.38 | $5.21B | |
99.56 | $12.15B | |
-13.02 | $6.77B | |
0 | $667.31M | |
5.71 | $4.20B | |
-16.72 | $4.12B | |
-11.26 | $1.41M | |
-0.12 | $44.01M | |
-1.51 | $23.68M | |
-0.41 | $4.19M | |
-0.18 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Iovance Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Iovance Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Iovance Biotherapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Iovance Biotherapeutics, Inc. (IOVA)?
What is the highest PE Ratio for Iovance Biotherapeutics, Inc. (IOVA)?
What is the 3-year average PE Ratio for Iovance Biotherapeutics, Inc. (IOVA)?
What is the 5-year average PE Ratio for Iovance Biotherapeutics, Inc. (IOVA)?
How does the current PE Ratio for Iovance Biotherapeutics, Inc. (IOVA) compare to its historical average?